Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine

Giulia Bianchi, Giordano Vitali, Augusto Caraceni, Sabrina Ravaglia, Giuseppe Capri, Sante Cundari, Claudio Zanna, Luca Gianni

Research output: Contribution to journalArticle

Abstract

Acetyl-L-carnitine (ALC) improves non-oncological neuropathies. We tested oral ALC (1 g tid) for 8 weeks in 25 patients with neuropathy grade ≥3 (common toxicity criteria - CTC) during paclitaxel or cisplatin therapy, or grade ≥2 persisting for at least three months after discontinuing the drugs. An independent neurologist assessed patients before and after ALC. All patients except one reported symptomatic relief, and only two described grade 1 nausea. The sensory neuropathy grade improved in 15 of 25 (60%), and motor neuropathy in 11 of 14 patients (79%). Total neuropathy score (TNS) that included neurophysiological measures improved in 23 (92%). Amelioration of sensory amplitude and conduction velocity (sural and peroneal nerves) was measured in 22 and 21 patients, respectively. Symptomatic improvement persisted in 12 of 13 evaluable patients at median 13 months after ALC. In view of its effect in improving established paclitaxel- and cisplatin-neuropathy, we recommend ALC testing in preventing progression or revert symptoms during neurotoxic chemotherapy.

Original languageEnglish
Pages (from-to)1746-1750
Number of pages5
JournalEuropean Journal of Cancer
Volume41
Issue number12
DOIs
Publication statusPublished - Aug 2005

Keywords

  • Acetyl-L-carnitine
  • Chemotherapy-neurotoxicity
  • Paclitaxel or cisplatin neuropathy
  • Sensory-neurotoxicity

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine'. Together they form a unique fingerprint.

  • Cite this